[1. Yang GK, Jooyen C, Srinivasan C. Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA. 1996;93:1156-1160.10.1073/pnas.93.3.1156400488577732]Search in Google Scholar
[2. Carroll D, Charo RA. The societal opportunities and challenges of genome editing. Genome Biology. 2015;16(1):1-9.10.1186/s13059-015-0812-0463474026537374]Search in Google Scholar
[3. Xue HY, Ji LJ, Gao AM, Liu P, He JD, Lu XJ. CRISPR-Cas9 for medical genetic screens: applications and future perspectives. J Med Genet. 2016;53:91-97.10.1136/jmedgenet-2015-10340926673779]Search in Google Scholar
[4. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429-5433.10.1128/jb.169.12.5429-5433.19872139683316184]Search in Google Scholar
[5. Makarova SK, Haft DH, Barrangou R. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 2011;9:467-477.10.1038/nrmicro2577338044421552286]Search in Google Scholar
[6. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.10.1126/science.1225829628614822745249]Search in Google Scholar
[7. Lokody I. Correcting genetic defects with CRISPR-Cas9. Nat Rev Genet. 2014; 15:63.10.1038/nrg365624342922]Search in Google Scholar
[8. Burgess JD. In vivo correction of genetic disease in adult mice. Nat Rev Genet. 2014; 15:291.10.1038/nrg3731]Search in Google Scholar
[9. Burgess JD. Technology: A CRISPR genome-editing tool. Nat Rev Genet. 2013;14: 80-81.]Search in Google Scholar
[10. Blake W, Esther VD, Jelle BB, el al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. PNAS. 2011;108(25): 10092-10097.10.1073/pnas.1102716108312184921536913]Search in Google Scholar
[11. Josiane EG, Marie-E`ve D, Manuela V, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468: 67-72.10.1038/nature0952321048762]Search in Google Scholar
[12. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. 2013;2(3):130-143.]Search in Google Scholar
[13. Ledford H. Alternative CRISPR system could improve genome editing. Nature. 2015; 526:17.10.1038/nature.2015.1843226432219]Search in Google Scholar
[14. Bernd Z, Jonathan SG, Omar OA. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell. 2015;163(3):759-771.10.1016/j.cell.2015.09.038463822026422227]Search in Google Scholar
[15. Lander ES. The Heroes of CRISPR. Cell. 2016;164(1-2):18-28.10.1016/j.cell.2015.12.04126771483]Search in Google Scholar
[16. CRISPR-Cpf1 May Outsnip CRISPR-Cas9. GEN News Highlights. http://www.genengnews.com/gen-news-highlights/crispr-cpf1-mayoutsnip-crispr-cas9/81251791/. [ accessed 26.Feb.2015].]Search in Google Scholar
[17. Scientists discover new system for human genome editing with potential to increase power and precision of genome engineering. Broadinstitute News. https://www.broadinstitute.org/news/7272. [accessed 23.Feb.2016].]Search in Google Scholar
[18. Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5+ stem cell. Nat Med. 2012;18, 618-623.]Search in Google Scholar
[19. Gerald S, Koo BK, Sasselli V. Functional Repair of CFTR by CRISPR/ Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients. Cell. 2013;13(6): 653-658.]Search in Google Scholar
[20. Patrick DH, Eric SL. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell. 2014;157(6): 1262-1278.10.1016/j.cell.2014.05.010434319824906146]Search in Google Scholar
[21. U.S National Library of Medicine. Huntington disease. Genetic Home Reference. https://ghr.nlm.nih.gov/condition/huntington-disease. 3 May 2016. [accessed 10.04.2016].]Search in Google Scholar
[22. U.S National Library of Medicine. HTT Huntington. Genetic Home Reference. https://ghr.nlm.nih.gov/gene/HTT. 3 May 2016. [accessed 10.04.2016].]Search in Google Scholar
[23. Bae S, Kweon J, Kim HS, Kim JS. Microhomology-based choice of Cas9 nuclease target sites. Nat Methods. 2014;11(7):705-706.10.1038/nmeth.301524972169]Search in Google Scholar
[24. Li HL, Gee P, Ishida K, Hotta A. Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods. 2015;101:27-35.]Search in Google Scholar
[25. Rajat M, Kiran M. Expanding the genetic editing tool kit: ZNFs, TALENs and CRISPR-Cas 9. The Journal of Clinical Investigation. 2014;124(10):4154-4161.10.1172/JCI72992419104725271723]Search in Google Scholar
[26. Sara R, Federica U, Melanie H,et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat. Cell Biol. 2012;14: 911-923.]Search in Google Scholar
[27. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2012;473: 221-225.10.1038/nature09915339296921490598]Search in Google Scholar
[28. Kannan R, Ventura A. The CRISPR revolution and its impact on cancer research. Swiss Med Wkly. 2015;145:w14230.10.4414/smw.2015.14230551243226661454]Search in Google Scholar
[29. Wen WS, Yuan ZM, Ma SJ, Xu J, Yuan DT. Crispr-cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies. Int J Cancer. 2016;138:6;1328-1336.10.1002/ijc.2962626044706]Search in Google Scholar
[30. Randall J, Sidi C, Yang Z, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014;159;440-455.10.1016/j.cell.2014.09.014426547525263330]Search in Google Scholar
[31. Hu Z, Yu L, Zhu D, et al. Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells. Biomed Res Int. 2014; Article ID:612823.10.1155/2014/612823412725225136604]Search in Google Scholar
[32. Tang L, Jacson KS, Zhihong L, Edwin C, Francis JH, Zhenfeng D. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Letters. 2016;373(1):109-118.10.1016/j.canlet.2016.01.030477267526806808]Search in Google Scholar
[33. Wen WS, Yuan ZY, Ma SJ, Xu J, Yuan DT. CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies. Int J Cancer. 2016;138(6):1328-36.10.1002/ijc.2962626044706]Search in Google Scholar
[34. Zhen S, Takahashi Y, Narita S, Yang YC, Li X. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.Oncotarget. 2016. DOI: 10.18632/ oncotarget.14072.10.18632/oncotarget.14072535473828030843]Search in Google Scholar
[35. Kim E, Hurtz C, Koehrer S, et al. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2016. doi.org/10.1182/blood-2016-06-722900.10.1182/blood-2016-06-722900537473228031181]Search in Google Scholar
[36. Huibin T, Joseph BS. CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy. EMBO. 2016;8(2):83-85.]Search in Google Scholar
[37. Xun LX, Leqiang S, Teng Y, et al. A CRISPR/Cas9 and Cre/Lox systembased express vaccine development strategy against reemerging Pseudorabies virus. Sci Rep. 2016; 6:19176.10.1038/srep19176472603626777545]Search in Google Scholar
[38. Money of the genes: CRISPR attracts a lot of investors. News & Tips. 2016. http://allcompanies.website/2016/01/25/money-of-the-genescrispr-attracts-a-lot-of-investors/. [accesed 13.02.2016].]Search in Google Scholar
[39. Wang G, Zhao N, Berkhout B, Das AT, et al. A Combinatorial CRISPRCas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures. Cell Rep. 2016;17(11):2819-2826.10.1016/j.celrep.2016.11.05727974196]Search in Google Scholar
[40. Edward AP, Ryan BP, Benjamin JF, Jeffrey SG, Aijaz A, Robert GG. Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep. 2016;15(4):237-244.10.1007/s11901-016-0315-9511229427917363]Search in Google Scholar
[41. Zhengyan F, Botao Z, Wona D, et al. Efficient genome editing in plants using a CRISPR/Cas system. Cell Res. 2013; 23:1229-1232.10.1038/cr.2013.114379023523958582]Search in Google Scholar
[42. Mercx S, Tollet J, Magy B, Navarre C, Boutry M. Gene Inactivation by CRISPR-Cas9 in Nicotiana tabacum BY-2 Suspension Cell. Front Plant Sci. 7:40. doi: 10.3389/fpls.2016.00040 http://dx.doi.org/10.3389/fpls.2016.00040. [accesed 01.02.2016].]Search in Google Scholar
[43. Lombardo L, Coppola G, Zelasco S. New Technologies for Insect-Resistant and Herbicide-Tolerant Plants. Trends Biotechnol. 2016;34(1):49-57.10.1016/j.tibtech.2015.10.00626620971]Search in Google Scholar
[44. Ain QU, Chung JY, Kim JH. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release. 2015;205:120-127.10.1016/j.jconrel.2014.12.03625553825]Search in Google Scholar
[45. Bing S, Liz HM, Yi G, Ying P. The Rise of CRISPR/Cas for Genome Editing in Stem Cells. Stem Cells Int. 2016;Volume 2016:17 pages. Article ID 8140168: doi:10.1155/2016/8140168.]Search in Google Scholar
[46. Cho S W, Kim S, Kim Y, et al. Analysis of off-target effects of CRISPR/ Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014; 24:132-141.10.1101/gr.162339.113387585424253446]Search in Google Scholar
[47. Tang L, Jacson KS, Zhihong L, Edwin C, Francis JH, Zhenfeng D. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Lett. 2016;373(1):109-118.10.1016/j.canlet.2016.01.030477267526806808]Search in Google Scholar
[48. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84-88.10.1126/science.aad5227471494626628643]Search in Google Scholar
[49. Julie S, Jonathan W, David G. Opposition mounts to genetic modification of human embryos. http://mobile.reuters.com/article/healthNews/idUSKBN0TK33F20151201. [accesed 10.02.2016].]Search in Google Scholar
[50. Puping L, Yanwen X, Xiya Z et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell. 2015; 6(5):363-372.10.1007/s13238-015-0153-5441767425894090]Search in Google Scholar
[51. Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014;514:380-384.10.1038/nature13589419993725119044]Search in Google Scholar
[52. Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014:159(2):440-450.10.1016/j.cell.2014.09.014426547525263330]Search in Google Scholar
[53. Lu XJ, Qi X, Zheng DH, Ji LJ. Modeling cancer processes with CRISPRCas9. Trends Biotechnol. 2015;33:317-319.10.1016/j.tibtech.2015.03.00725908505]Search in Google Scholar
[54. Katerine S, Michael B, Annelien B, et al. CRISPR germline engineering - the community speaks. Nature Biotechnology. 2015; 33:478-486.10.1038/nbt.322725965754]Search in Google Scholar
[55. Ewen C. UK scientists gain licence to edit genes in human embryos. Nature. 2016;530,18-19.10.1038/nature.2016.1927026842037]Search in Google Scholar
[56. Yanfang F, Jennifer AF, Cyd K. High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.10.1038/nbt.2623377302323792628]Search in Google Scholar
[57. Roni A. UNESCO panel of experts calls for ban on “editing” of human DNA to avoid unethical tampering with hereditary traits. UNESCO Media Service. 10 May 2016. ]Search in Google Scholar